Guardant Health Surges Following FDA Approval and Cancer Screening Momentum

Guardant Health (GH) has seen a significant surge in its stock value, driven by recent FDA approval for its products and growing momentum in the cancer screening market. This development positions the company for potential growth in the healthcare sector.